<DOC>
	<DOCNO>NCT00629759</DOCNO>
	<brief_summary>The primary purpose study determine maximum tolerable dose ( MTD ) and/or maximum feasible dose ( MFD ) , well evaluate safety JX-594 ( Pexa-Vec ) inject within hepatic carcinoma tumor .</brief_summary>
	<brief_title>A Study Recombinant Vaccinia Virus Evaluate Safety Efficacy Transdermal Injection Within Tumor Patients With Primary Metastatic Hepatic Carcinoma</brief_title>
	<detailed_description>Patients treat JX-594 every three week progression site ( ) injection patient receive maximum 4 treatment ; four additional cycle administer patient objective response inject tumor ( ) ( i.e . 8 total treatment possible ) . Study dose level 1e8 pfu , 3e8 pfu , 1e9 pfu 3e9 pfu per treatment . Standard Phase I dose-escalation guideline use , 2-6 patient enrol per cohort ( 3 dose-limiting toxicity report ) .</detailed_description>
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Age ≥ 18 year Patients hepatic carcinoma ( primary metastatic ) clinically histologically confirm tumor ( ≤10cm maximum diameter ) progressing ( refractory standard treatment ) despite regular treatment transdermally access injection needle imagingguided procedure Tumor progression despite undergoing regular treatment surgery , transarterial chemoembolization , chemotherapy , radiotherapy Performance score : Karnofsky Performance Score ( KPS ) ≥70 Expected survival least 16 week For patient sexually active , able willing use contraceptive three month period take JX594 WBC &gt; 3,500 cells/mm3 ANC &gt; 1,500 cells/mm3 Hemoglobin &gt; 10g/dL Platelet count &gt; 75,000 plts/mm3 Serum creatinine &lt; 1.5 mg/dL AST , ALT &lt; 2.5 x ULN Total bilirubin ≤ 2.0 mg/dL In patient primary HCC , Child Pugh A B Able/willing sign IRB/IEC/REBapproved write consent form Able willing comply study procedure followup examination Pregnant nursing infant Known infection HIV Clinically significant active infection uncontrolled medical condition consider high risk investigational new drug treatment Significant immunodeficiency due underlie illness ( e.g . hematological malignancy , congenital immunodeficiency and/or HIV infection/AIDS ) and/or medication ( e.g . highdose systemic corticosteroid ) Patients household contact significant immunodeficiency History exfoliative skin condition ( e.g . severe eczema , ectopic dermatitis , similar skin disorder ) stage require systemic therapy Severe unstable cardiac disease Use adrenal cortical hormone drug immunosuppressant within four week study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Jennerex</keyword>
	<keyword>unresectable liver tumor</keyword>
	<keyword>primary liver cancer</keyword>
	<keyword>metastatic liver cancer</keyword>
	<keyword>oncolytic virus</keyword>
	<keyword>vaccinia virus</keyword>
	<keyword>Pexa-Vec</keyword>
</DOC>